These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32655572)

  • 1. Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction.
    Barra C; Ackaert C; Reynisson B; Schockaert J; Jessen LE; Watson M; Jang A; Comtois-Marotte S; Goulet JP; Pattijn S; Paramithiotis E; Nielsen M
    Front Immunol; 2020; 11():1304. PubMed ID: 32655572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.
    Sekiguchi N; Kubo C; Takahashi A; Muraoka K; Takeiri A; Ito S; Yano M; Mimoto F; Maeda A; Iwayanagi Y; Wakabayashi T; Takata S; Murao N; Chiba S; Ishigai M
    MAbs; 2018; 10(8):1168-1181. PubMed ID: 30199322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying MAPPs Assays to Assess Drug Immunogenicity.
    Karle AC
    Front Immunol; 2020; 11():698. PubMed ID: 32373128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development.
    Lee MV; Saad OM; Wong S; LaMar J; Kamen L; Ordonia B; Melendez R; Hassanzadeh A; Chung S; Kaur S
    Front Immunol; 2023; 14():1295285. PubMed ID: 38022649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands.
    Paul S; Karosiene E; Dhanda SK; Jurtz V; Edwards L; Nielsen M; Sette A; Peters B
    Front Immunol; 2018; 9():1795. PubMed ID: 30127785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins.
    Attermann AS; Barra C; Reynisson B; Schultz HS; Leurs U; Lamberth K; Nielsen M
    Immunology; 2021 Feb; 162(2):208-219. PubMed ID: 33010039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.
    Zhao W; Sher X
    PLoS Comput Biol; 2018 Nov; 14(11):e1006457. PubMed ID: 30408041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integral Use of Immunopeptidomics and Immunoinformatics for the Characterization of Antigen Presentation and Rational Identification of BoLA-DR-Presented Peptides and Epitopes.
    Fisch A; Reynisson B; Benedictus L; Nicastri A; Vasoya D; Morrison I; Buus S; Ferreira BR; Kinney Ferreira de Miranda Santos I; Ternette N; Connelley T; Nielsen M
    J Immunol; 2021 May; 206(10):2489-2497. PubMed ID: 33789985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.
    Di Ianni A; Fraone T; Balestra P; Cowan K; Riccardi Sirtori F; Barbero L
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37833075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
    Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
    Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enabling Routine MHC-II-Associated Peptide Proteomics for Risk Assessment of Drug-Induced Immunogenicity.
    Steiner G; Marban-Doran C; Langer J; Pimenova T; Duran-Pacheco G; Sauter D; Langenkamp A; Solier C; Singer T; Bray-French K; Ducret A
    J Proteome Res; 2020 Sep; 19(9):3792-3806. PubMed ID: 32786679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of MHC-Bound Peptides from Dendritic Cells Infected with Salmonella enterica Strain SL1344: Implications for a Nontyphoidal Salmonella Vaccine.
    Karunakaran KP; Yu H; Jiang X; Chan Q; Goldberg MF; Jenkins MK; Foster LJ; Brunham RC
    J Proteome Res; 2017 Jan; 16(1):298-306. PubMed ID: 27802388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.
    Wang S; Li J; Chen X; Wang L; Liu W; Wu Y
    Immunol Res; 2016 Aug; 64(4):908-18. PubMed ID: 27094547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major Histocompatibility Complex Binding, Eluted Ligands, and Immunogenicity: Benchmark Testing and Predictions.
    Paul S; Grifoni A; Peters B; Sette A
    Front Immunol; 2019; 10():3151. PubMed ID: 32117208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes.
    Hartman K; Steiner G; Siegel M; Looney CM; Hickling TP; Bray-French K; Springer S; Marban-Doran C; Ducret A
    Biology (Basel); 2023 Sep; 12(9):. PubMed ID: 37759665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encounter with antigen-specific primed CD4 T cells promotes MHC class II degradation in dendritic cells.
    Furuta K; Ishido S; Roche PA
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19380-5. PubMed ID: 23129633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.